Worg Pharmaceuticals (Zhejiang) Co. Ltd. raised ¥1.1 billion (US$152 million) in a series C round to develop its therapies for allergy and autoimmune diseases, as well as to expand into the global market.
Coloplast A/S agreed to acquire wound care company Kerecis Ehf for up to $1.3 billion in a bid to strengthen its presence in the high-growth, U.S.-centric biologics segment. Kerecis has developed a technology which uses intact fish skin from Atlantic cod to treat chronic wounds. It has around 5% share of the U.S. biologics market.
Med-tech companies raised a total of $1.7 billion in financings in June, a decrease of 21.64% compared to the same month last year. Volume of med-tech financings are also down: 30 in June 2023 compared to 41 in June 2022. Numbers are down significantly from the 56 financings worth $4.45 billion in June 2021, 76 financings worth $5.27 billion in June 2020, and 47 worth $2.08 billion in June 2019.
Thirona BV has been awarded $2.73 million in funding from the European Innovation Council (EIC) to fast-track the development of its artificial intelligence (AI)-based lung platform to analyze chest CT imaging. In competition with 554 other submissions, Thirona was one of 51 innovative technology companies awarded the EIC accelerator program grant, the total budget for which is €261 million (US$286.28 million) in 2023.